Clinical Monograph: Ozempic 2 mg (Semaglutide)

Ozempic 2 mg pre-filled injection pen. Source: Merit Pharmaceutical

1. Classification and Chemical Overview

Semaglutide is a synthetic human GLP-1 analogue exhibiting 94% structural sequence homology to native human GLP-1. Its structure is engineered with an amino acid substitution at position 8 (alanine to $\alpha$-aminobutyric acid) to protect against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), along with a C18​ fatty diacid chain attached at position 26 via a linker to facilitate reversible binding to serum albumin. Under the Anatomical Therapeutic Chemical (ATC) classification system, semaglutide is indexed under A10BJ06.

Ozempic 2 mg represents the highest approved therapeutic maintenance dosage strength for type 2 diabetes. It is supplied as a single-patient-use pre-filled pen containing 8 mg of semaglutide in 3 mL of solution ($2.68\text{ mg/mL}$), engineered to deliver 4 fixed weekly doses of 2 mg in a 0.75 mL injection volume. Across global regulatory jurisdictions (including the UK, EU, and US), Ozempic is classified as a Prescription Only Medicine (POM).

2. Mechanism of Action and Pharmacodynamics

Semaglutide acts as a selective GLP-1 receptor agonist that binds to and activates the GLP-1 receptor, triggering downstream multi-organ metabolic signaling:

• Glucose-Dependent Insulin Secretion: Stimulates pancreatic $\beta$-cell exocytosis of insulin in the presence of elevated blood glucose levels.

• Glucagon Suppression: Inhibits inappropriate postprandial glucagon secretion from pancreatic $\alpha$-cells without impairing normal glucagon response to hypoglycaemia.

• Gastric Emptying Delay: Slows early postprandial gastric motility, attenuating the rate of post-meal systemic glucose absorption.

• Centrally Mediated Appetite Control: Acts on hypothalamic brain regions to increase satiety and decrease hunger and food intake.

• Cardiovascular Protection: Reduces systemic vascular inflammation, improves endothelial function, and lowers systolic blood pressure.

The 2 mg weekly dose achieves maximal steady-state GLP-1 receptor activation in patients with type 2 diabetes who require additional glycemic control beyond the 1 mg weekly dose.

3. Approved Clinical Indications and Therapeutic Scope

Licensing for Ozempic 2 mg includes:

• Type 2 Diabetes Mellitus (Glycemic Control): Adjunct to diet and exercise to improve glycemic control in adults with insufficiently controlled type 2 diabetes mellitus (as monotherapy when metformin is inappropriate, or in combination with other anti-hyperglycaemic agents).

• Cardiovascular Risk Reduction: Reduction in the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Dosing & Titration Regimen: Therapy is initiated at 0.25 mg once weekly for 4 weeks, followed by an increase to 0.5 mg once weekly for at least 4 weeks. If additional glycemic control is required, the dose may be increased to 1 mg once weekly for at least 4 weeks, and finally escalated to the 2 mg once weekly maximum maintenance dose.

Off-Label & Distinction Warning: Ozempic is officially licensed for type 2 diabetes mellitus and cardiovascular risk reduction in type 2 diabetes. While semaglutide produces weight loss, dedicated higher-dose formulations (such as Wegovy up to 2.4 mg) carry the explicit regulatory approval for chronic weight management in non-diabetic populations.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Absolute bioavailability following subcutaneous administration is approximately 89%. Maximum plasma concentration (Cmax​) occurs between 1 and 3 days (Tmax​) post-dose.

• Distribution: Semaglutide is extensively bound to plasma proteins (> 99%, primarily human serum albumin). The mean volume of distribution (Vd​) is approximately $12.5\text{ L}$.

• Biotransformation: Semaglutide is extensively metabolised through proteolytic cleavage of the peptide backbone and sequential $\beta$-oxidation of the fatty acid side chain. It does not rely on cytochrome P450 (CYP) enzymatic pathways for elimination.

• Elimination: Elimination occurs via renal and faecal pathways following metabolic breakdown into peptide fragments. Clearance is low ($\approx 0.05\text{ L/h}$), resulting in an elimination half-life (t1/2​) of approximately 1 week (7 days), which supports once-weekly subcutaneous dosing.

5. Physiological Effects and Adverse Event Spectrum

Semaglutide produces sustained reductions in glycated haemoglobin (HbA1c​), lowers fasting and postprandial plasma glucose concentrations, reduces total body weight, and lowers systolic blood pressure.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Nausea, diarrhoea, hypoglycaemia (when used concomitantly with sulfonylureas or insulin).

• Common ($\ge 1/100$ to $<1/10$): Vomiting, abdominal pain, constipation, dyspepsia, gastritis, gastro-oesophageal reflux disease, eructation, flatulence, abdominal distension, fatigue, dizziness, elevated lipases/amylase, diabetic retinopathy complications.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Acute pancreatitis, cholelithiasis, injection site reactions (erythema, pruritus), dysgeusia, sinus tachycardia.

• Rare (<1/1,000): Anaphylactic reactions, angioedema.

6. Contraindications, Drug Interactions, and Clinical Precautions

Controindicazioni

• Personal or family history of Medullary Thyroid Carcinoma (MTC).

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Known severe hypersensitivity to semaglutide or formulation excipients.

• Pregnancy and lactation (discontinue at least 2 months prior to a planned pregnancy).

Key Drug Interactions

• Oral Medications: Semaglutide-induced delays in gastric emptying can alter the absorption rate of concomitantly administered oral medications, particularly those with a narrow therapeutic index.

• Insulin Secretagogues and Insulin: Co-administration with sulfonylureas or insulin significantly increases the risk of severe hypoglycaemia; reductions in secretagogue or insulin doses are typically required.

Clinical Precautions and Monitoring

• Acute Pancreatitis: Patients should be monitored for signs of acute pancreatitis (persistent, severe abdominal pain radiating to the back). If suspected, treatment must be discontinued immediately.

• Diabetic Retinopathy: Rapid improvement in glycemic control in patients with pre-existing diabetic retinopathy has been associated with temporary worsening of retinal complications.

• Renal Function & Dehydration: Gastrointestinal adverse effects (vomiting, diarrhoea) can cause volume depletion leading to acute kidney injury. Patients must maintain adequate fluid intake.